CADTH’s timely assessment of interventions for chronic inflammatory demyelinating polyneuropathy (CIDP) compared IVIg with alternative treatments, including corticosteroids and plasma exchange. Questions surrounding the comparative health outcomes and costs of potential treatment options for CIDP and the cost and availability of IVIg highlighted the need for this assessment.
This complete report has been extensively reviewed by external clinical and methodological experts:
- Technology Report (119 pages)
In support of the CADTH assessment, the following summaries have been developed: